- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Paxlovid may reduce all-cause mortality in pediatric patients with SARS-CoV-2 infection: Study
A recent study published in the Nature Communications addressed the significant gap in data regarding the use of the antiviral combination nirmatrelvir/ritonavir for pediatric patients infected with SARS-CoV-2. This newly conducted target trial emulation study provides critical insights into the effectiveness and safety of the antiviral medication in non-hospitalized children of 12 to 17 years old who contracted the Omicron variant of COVID-19.
The study evaluated pediatric patients diagnosed with SARS-CoV-2 from March 16, 2022 to February 5, 2023. The patients were considered exposed if they received outpatient treatment with nirmatrelvir/ritonavir within five days of symptom onset or a COVID-19 diagnosis. The primary outcome measured was the 28-day all-cause mortality or hospitalization, while secondary outcomes included 28-day in-hospital disease progression, COVID-19-specific hospitalization, multisystem inflammatory syndrome in children (MIS-C), acute liver injury, acute renal failure and acute respiratory distress syndrome.
A total of 49,378 eligible pediatric patients were included in this comprehensive study. The findings suggest that nirmatrelvir/ritonavir treatment was significantly associated with a reduction in 28-day all-cause hospitalization. Also, the absolute risk reduction was 0.23% (with a 95% confidence interval of 0.19% to 0.31%) and the relative risk was 0.66 (with a 95% confidence interval of 0.56 to 0.71). There were no observed events of mortality, in-hospital disease progression or adverse clinical outcomes among the patients treated with nirmatrelvir/ritonavir.
These results underline the potential of nirmatrelvir/ritonavir to significantly reduce the hospitalization risks for non-hospitalized pediatric patients infected with the Omicron variant of COVID-19. The antiviral therapy appears to provide a robust defense against severe outcomes in children and adolescents, thereby offering a valuable tool in managing the ongoing pandemic.
The study highlights the importance of timely intervention, as the efficacy of the treatment was assessed based on administration within five days of symptom onset or diagnosis. This suggests that early outpatient treatment could be key in reducing severe disease progression in pediatric COVID-19 cases.
Research like these is critical in shaping effective treatment protocols and ensuring that vulnerable populations, including children and adolescents, receive the best possible care. The findings of this study could pave way for further research and potentially wider use of nirmatrelvir/ritonavir in pediatric COVID-19 treatment to reduce the burden of the disease on younger populations.
Reference:
Wong, C. K. H., Lau, K. T. K., Au, I. C. H., Chan, S. H. S., Lau, E. H. Y., Cowling, B. J., & Leung, G. M. (2024). Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12–17 years following SARS-CoV-2 Omicron infection: A target trial emulation. In Nature Communications (Vol. 15, Issue 1). Springer Science and Business Media LLC. https://doi.org/10.1038/s41467-024-49235-8
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751